Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Lexston Life Sciences Corp. (C:LEXT)

Business Focus: N/A

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for LEXT within the last 6 months
See all filings within the past 6 months

Company News

Jan 14, 2022 16:00 ET
Lexston Comments On Recent Market Activity
Vancouver, British Columbia – TheNewswire - January 14, 2022. Lexston Life Sciences Corp. (the “Company” or “Lexston”) (CSE:LEXT) (CNSX:LEXT.CN) (OTC:LEXTF)  wishes to make the following statements regarding certain market activity surrounding its common shares (the” Shares”) traded on the OTCQB market pursuant to the request of OTC Markets Group Inc. (“OTC Markets”).
Read full article
Jan 12, 2022 06:30 ET
Lexston Announces a Memorandum Of Understanding to Collabborate on Psychedelics Research and Development with Alvarius Research Inc.
Vancouver, British Columbia – TheNewswire - January 12, 2022. Lexston Life Sciences Corp. (the “Company” or “Lexston”) (CSE:LEXT) (CNSX:LEXT.CN) (OTC:LEXTF) is pleased to announce the signing of a Memorandum of Understanding (the “MOU”) between its wholly owned subsidiary Egret Bioscience Ltd. (“Egret”) and Alvarius Research Inc. (“Alvarius”; a wholly owned subsidiary of Lighthouse Genomics Inc.), a leading research and development company focused on ex situ conservation and genomic resource development for the Colorado River toad (Incilius alvarius).
Read full article
See more news stories

Valuation Ratios

Price to Sales - TTM
Price to Book - most recent quarter
Price to Cash Flow per share - TTM
Price to Free Cash Flow per share - TTM
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Dec 31, 202100
Dec 15, 202100
Nov 30, 202100
See Short Report

Business Summary

Sector:  N/A Industry:  N/A

See business summary



Search (past week) for $LEXT.CA

  • No tweets found